ILMN Overview

Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.

Wall Street analysts forecast ILMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is133.54 USD with a low forecast of 40.50 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Illumina Inc revenue for the last quarter amounts to 1.16B USD, increased 4.98

Illumina Inc. EPS for the last quarter amounts to 2.18 USD, increased 84.75

Illumina Inc (ILMN) has 8600 emplpoyees as of March 31 2026.

Today ILMN has the market capitalization of 18.47B USD.